Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan…

By Troy Z. Horvat, N. Adel, T. Dang, Parisa Momtaz, M. Postow, M. Callahan, R. Carvajal, M. Dickson, S. D’Angelo, K. Woo and 3 more. Journal of Clinical Oncology, 2015

926 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/59957b4b4cb1ac05b3a4caca6130b04eaddbf3d4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Postow
2. J. Wolchok
3. C. Robert
4. Yang Xie
5. M. Lacouture
6. J. Goldberg

In Oncology

1. M. Postow
2. J. Wolchok
3. C. Robert
4. K. Kerr
5. K. Schindler
6. L. Connell
7. D. Page
8. J. Haanen

Citations in the corpus

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Importantly, so far there is no evidence that the clinical outcome of patients on ICPis is affected by the use of immunosuppressive agents for the management of immune-related toxicities [7, 18].”
• Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients (2017, background): “However, a substantial number of patients fail to benefit from ICT, and others experience severe autoimmune adverse events including dermatitis, colitis, hepatitis, and hypophysitis [2].”
• Management of toxicities of immune checkpoint inhibitors. (2016, background): “Time to treatment failure and overall survival were no worse in the steroid-requiring group [83].”
• New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, background): “events (IRAEs) were reported in up to 85% of patients after treatment with ipilimumab [16] and up to 70% after”
• Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “Some retrospective analyses suggest that use of corticosteroids for the management of irAEs is not associated with inferior results of therapy [31, 32] but, due Fig.”
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2015, background): “Standard treatment algorithms for irAEs have been developed that utilize immune-modulating medications including corticosteroids, antihistamines, antitumor necrosis factor medications and calcineurin inhibitors, which may quell the inflammatory response, without eliminating the antitumor immune resp”
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “Standard treatment algorithms for irAEs have been developed that utilize immune-modulating medications including corticosteroids, antihistamines, antitumor necrosis factor medications and calcineurin inhibitors, which may quell the inflammatory response, without eliminating the antitumor immune resp”